Atlas Capital Advisors Inc. purchased a new stake in VanEck Biotech ETF (NASDAQ:BBH – Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 5,700 shares of the company’s stock, valued at approximately $1,079,000.
Other institutional investors have also added to or reduced their stakes in the company. Empowered Funds LLC acquired a new stake in VanEck Biotech ETF during the fourth quarter worth about $38,000. Flagship Harbor Advisors LLC bought a new position in VanEck Biotech ETF during the fourth quarter worth about $47,000. Allworth Financial LP lifted its stake in VanEck Biotech ETF by 255.0% during the fourth quarter. Allworth Financial LP now owns 426 shares of the company’s stock worth $81,000 after purchasing an additional 306 shares during the period. Huntington National Bank bought a new position in VanEck Biotech ETF during the fourth quarter worth about $132,000. Finally, Cibc World Market Inc. bought a new position in VanEck Biotech ETF during the third quarter worth about $204,000. 32.05% of the stock is owned by institutional investors and hedge funds.
VanEck Biotech ETF Stock Performance
Shares of BBH opened at $187.56 on Monday. VanEck Biotech ETF has a 12 month low of $150.18 and a 12 month high of $202.91. The company has a 50-day moving average price of $186.91 and a two-hundred day moving average price of $190.61.
VanEck Biotech ETF Company Profile
The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.
Featured Articles
- Five stocks we like better than VanEck Biotech ETF
- 3 ETFs Giving Ready-Made Access to the Discounted International Small-Cap Space
- What to Expect From Q2 Earnings as Tech Strength Broadens
- Viasat’s Orbiting Profits: Space Force Jackpot?
- Robinhood Wants a Bigger Role in IPOs—Here’s Why It Matters
Want to see what other hedge funds are holding BBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VanEck Biotech ETF (NASDAQ:BBH – Free Report).
Receive News & Ratings for VanEck Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
